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The effects of benzofury (5-APB) on the dopamine transporter and 5-HT2-
dependent vasoconstriction in the rat. 
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Abstract 
 
5-APB, commonly marketed as ‘benzofury’ is a new psychoactive substance and erstwhile 
‘legal high’ which has been implicated in 10 recent drug-related deaths in the UK. This drug 
was available on the internet and in ‘head shops’ and was one of the most commonly sold legal 
highs up until its recent UK temporary ban (UK Home Office). Despite its prominence, very 
little is known about its pharmacology. This study was undertaken to examine the 
pharmacology of 5-APB in vitro. We hypothesized that 5-APB would activate the dopamine 
and 5-HT systems which may underlie its putative stimulant and hallucinogenic effects.  
Autoradiographic studies showed that 5-APB displaced both [
125
I]RTI-121 and [
3
H]ketanserin 
from rat brain tissue suggesting affinity at the dopamine transporter and 5-HT2 receptor sites 
respectively. Voltammetric studies in rat accumbens brain slices revealed that 5-APB slowed 
dopamine reuptake, and at high concentrations caused reverse transport of dopamine. 5-APB 
also caused vasoconstriction of rat aorta, an effect antagonized by the 5-HT2A receptor 
antagonist ketanserin, and caused contraction of rat stomach fundus, which was reversed by the 
5-HT2B receptor antagonist RS-127445. These data show that 5-APB interacts with the 
dopamine transporter and is an agonist at the 5-HT2A and 5-HT2B receptors in the rat. Thus 5-
APB’s pharmacology is consistent with it having both stimulant and hallucinogenic properties. 
In addition, 5-APB’s activity at the 5-HT2B receptor may cause cardiotoxicity. 
 
Keywords:  
 
Benzofury, accumbens, prefrontal cortex, dopamine transporter, 5-HT2, vasoconstriction 
 
Abbreviations: 
 
5-APB: 5-(2-aminopropyl)benzofuran; ACMD: Advisory Council on the Misuse of Drugs; 
aCSF: artificial cerebrospinal fluid; AUC: area under the curve; DA: dopamine; MDMA: 3,4, 
methylenedioxymethamphetamine; MDA: 3,4-methylenedioxyamphetamine; LSD: lysergic 
acid diethylamide; PFC: prefrontal cortex; ROI: region of interest.  
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1. Introduction 
 
Until recently, two benzofuran compounds - 5- and 6-APB (5- and 6-(2-
aminopropyl)benzofuran) - were being sold as the “legal high”/”designer drug” ‘Benzofury’. 
These drugs are structurally related to two other recreational drugs; Ecstasy (3,4, 
methylenedioxymethamphetamine, MDMA) and 3,4-methylenedioxyamphetamine (MDA).  5-
and 6-APB are structural isomers and were first developed in the early 1990s (Monte et al., 
1993). There has been difficulty in separating the 5- and 6-APB isomers, and perhaps the 
occurrence of the 4-APB isomer, but chemical analysis can now differentiate these isomers 
(Stanczuk et al., 2013). Anecdotal user reports suggest that benzofury has entactogenic and 
stimulant effects and that 5-APB is more potent than 6-APB.  There is some suggestion that 
the drug may also have some psychedelic effects, but users do not appear to take 5-APB 
exclusively for this purpose.  In the UK, Benzofury has been implicated in about 10 deaths 
since 2011. In all cases, 5- or 6-APB was found at postmortem, although because of polydrug 
use, it is often difficult to attribute death to a single drug (ICDP, personal communications).  
Anecdotal user reports suggest that this drug can cause hyperthermia, insomnia, increased 
heart rate and anxiety with some users reporting adverse effects similar to those produced by 
Ecstasy (ACMD report).  
 
Psychostimulants are thought to mediate their rewarding effects through inhibition of the 
dopamine transporter or to cause direct dopamine release (Giros et al., 1996; Lee et al., 2001). 
Hallucinogenic drugs such as LSD, on the other hand, would be expected to have efficacy at 5-
HT2A receptors (Passie et. al, 2008). We thus first tested whether 5-APB could displace 
radioligands for the dopamine transporter and the 5-HT2 receptors in rat brain tissue. Most 
drugs of abuse, but especially stimulants, increase dopamine efflux within the nucleus 
accumbens (Di Chiara and Imperato, 1988; Willuhn et al., 2010). We next examined the effect 
of 5-APB in a functional study, using electrically evoked dopamine efflux in the rat accumbens 
brain slice, measured by fast cyclic voltammetry. Finally, given the potential cardiovascular 
effects of agonists at 5-HT2 receptors (Dawson and Moffatt 2012) we examined the effects of 
5-APB in displacing [
3
H]ketanserin from rat striatum and cortex and  in functional assays for 
both 5-HT2A agonist activity (rat aortic contraction; Villaźon et. al, 2002) and 5-HT2B agonist 
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activity (rat gastric fundus contraction; Baxter et. al 1994).  
 
2. Methods 
 
2.1. Animals 
 
Adolescent male Wistar rats aged 8 weeks (~200 g) were bred in-house and kept on a 12/12 h 
light/dark cycle, fed and watered ad libitum and housed 4 per cage. Animals were sacrificed by 
cervical dislocation without anaesthesia. All procedures were conducted in accordance with 
regulations under the UK Animals (Scientific Procedures) Act 1986. Male adolescent and not 
mature adult rats were used as human drug taking typically starts in adolescence; this is 
especially true for the novel psychoactive drugs which appear to be taken mostly by adolescent 
males, at least in the case of mephedrone (Vardakou et al., 2011; Carhart-Harris et al., 2011). 
 
2.2. Quantitative Autoradiography 
 
2.2.1. Chemicals 
   
The radioligand for the dopamine transporter, [
125
I]RTI- 121 (specific activity  81.4TBq/mM) 
and [
3
H]ketanserin for the 5-HT2 receptor (specific activity 1.976 TBq/mM) were purchased 
from Perkin Elmer. All chemicals apart from methysergide (Tocris Biosciences UK) were 
purchased from Sigma-Aldrich (Poole, UK). 5-APB was purchased from an internet supplier 
and chemically identified with GCMS and NMR. 
 
2.2.2. Rat brain tissue preparation. 
 
Rat brains were rapidly removed, frozen at -40°C using dry ice and isopentane and stored at -
80°C. Frozen brains were coronally cut into 20 µm sections in a rostro-caudal direction from 
+3.0 to +1.0 mm versus bregma to harvest the prefrontal cortex, nucleus accumbens and 
caudate-putamen (Paxinos and Watson, 2005). Sections were collected onto polysine-coated 
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slides and stored at -80
o
C prior to autoradiography. Six rat brains were used per radioligand 
assay. 
 
2.2.3. In vitro quantitative autoradiography: Dopamine transporter binding 
   
The autoradiography procedure was based on Strazielle et al. (1998). Striatal sections were 
preincubated in 0.05 M NaPB pH 7.4 and then incubated with 20 pM [
125
I]RTI121 in NaPB pH 
7.4 with increasing concentrations of 5-APB (0 - 30 µM) for 60 minutes at room temperature. 
Non-specific binding was assessed in the presence of 200 µM nomifensine. Air-dried slides 
were apposed to Kodak BioMax MR films for 3 days; autoradiograms were analysed using 
MCID™, Version 7.0, Imaging Research Inc., Interfocus Ltd, U.K. Flat-field correction was 
applied. Relative optical density was measured in the accumbens shell and dorso-lateral striatal 
regions of interest (ROIs); both left and right hemisphere ROIs were sampled from triplicate 
sections and their means were calculated to assess the specific binding.  
 
2.2.4. In vitro quantitative autoradiography: 5-HT2A receptor binding 
 
The procedure was based on Sato et al. (2010). Triplicate brain sections were preincubated in 
0.05 M Tris buffer pH 7.4 and then incubated with 1 nM [
3
H]ketanserin in 0.05 M Tris buffer 
pH 7.4 with 1 µM prazosin (to block binding to adrenergic receptors) and 100 nM 
tetrabenazine (to block binding to the vesicular transporter) for 60 minutes at room 
temperature; increasing concentrations of 5-APB were added (0 - 30 µM). Non-specific 
binding was assessed in the presence of 200 µM methysergide. Air-dried slides were apposed 
to Kodak BioMax MR films for 8 weeks; autoradiograms were analysed using MCID™, 
Version 7.0, Imaging Research Inc., Interfocus Ltd, U.K., with flat field correction. Relative 
optical density was measured in the prefrontal cortex (PFC) and accumbens shell regions of 
interest (ROIs); both left and right ROIs were sampled from triplicate sections and their means 
were calculated to assess the specific binding. Sections of inferior quality were excluded from 
quantitative analysis hence n=5 in Figure 1D. 
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The nucleus accumbens and PFC were chosen considering their involvement in brain 
responses to drugs of abuse (e.g. Koob and Volkov, 2010) and the high density of the 5-HT2A 
receptor in these brain areas (Sato et al., 2010). 
 
2.3. Fast cyclic voltammetry in accumbens brain slices 
 
2.3.1. Drugs and salts 
 
Artificial cerebrospinal fluid (aCSF) was prepared as previously described (Brierley and 
Davidson, 2012): NaCl 126 mM; KCl 4 mM; KH2PO4 1.4 mM; MgSO4 1.3 mM; 
NaHCO3 26 mM; D-glucose 4 mM; CaCl2 2.4 mM in de-ionized water and 
oxygenated with 95%O2 / 5%CO2 at room temperature. These chemicals were purchased from 
Sigma-Aldrich (Poole, UK).  
 
2.3.2. Measurement of dopamine efflux with fast cyclic voltammetry 
 
Briefly, a triangular voltage waveform (Figure 2d) was applied to a carbon fibre 
microelectrode (7 µm x 50 µm tip, as previously described; Brierley and Davidson, 2012) 
which oxidized monoamines at about 600 mV versus a Ag/AgCl reference electrode. The 
resulting current at the electrode surface was recorded. Calibration of this electrode in a known 
concentration of dopamine (Figure 2a and 2e) allowed the recorded Faradaic current to be 
converted to the concentration of dopamine. Voltammetric scans conducted at 8 Hz were 
performed by a Millar Voltammetric Analyser (PD Systems, West Molesey, UK), with the 
evoked current of the complete scan at the electrode and signals sampled at the oxidation peak 
(Figure 2d-f) captured using a CED1401 micro3 analogue-to-digital converter (Cambridge 
Electronic Design, UK) and Spike2 v7.1 data capture software. 
 
2.3.3. Accumbens brain slice preparation 
 
Following cervical dislocation brains were rapidly removed under ice-cold aCSF and 400 μm 
sections were taken rostro-caudally from approximately +2.2 to +1.0 mm versus bregma 
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(Paxinos & Watson, 1986) using a vibratome. A slice was transferred to a laminar flow 
recording chamber supplied with aCSF via gravity feed, at a flow rate of 2 ml/min and 
temperature in the recording chamber at 32.5 ± 0.5 °C. Slices were left to equilibrate in this 
environment for 40 min prior to electrical stimulation. The recording microelectrode was 
placed in the accumbens shell at the start of the equilibration period to monitor background 
dopamine levels, as under certain circumstances (such as poor slice health or increased 
temperature) large spontaneous release of dopamine can occur (Davidson et al., 2011). We 
recorded in the accumbens shell because 5-HT2A receptors are most prevalent in this part of the 
striatum (Mijnster et al., 1997; and see Figure 1) and the shell is thought to show the greatest 
acute effect of stimulants (Pontieri et la., 1996). 
 
2.3.4. Electrical stimulation protocol 
 
Dopamine efflux was evoked by a stimulation protocol designed to replicate the phasic burst 
firing pattern typical of midbrain dopamine neurons during presentation of salient reward 
related stimuli, such as drugs of abuse (Hyland et al., 2002). A train of 10 x 1 ms 10 mA pulses 
was applied at a frequency of 20 Hz, with stimulus trains applied every 5 min. Stimulus train 
parameters were programmed into the Spike 7 data capture program and applied to a bipolar 
steel electrode (A-M Systems, WA, USA), with tips approximately 300 μm apart, and 200 μm 
from the recording electrode. 
 
2.3.5. Data acquisition and analysis 
 
Changes in Faradaic current sampled at the dopamine oxidation peak were plotted by the 
Spike2 software. For each efflux event the area under the curve (AUC) was calculated 
(Yorgason et al., 2011). Stimulated efflux events were initiated every 5 min and following 3 
stable consecutive baseline events 5-APB was added (Fig 2b). All data was expressed as a 
percentage of the mean pre-drug AUC.  
 
2.4. 5-HT2 receptor assays in peripheral tissue  
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Male Wistar rats (200-300 g) were killed by cervical dislocation and the thoracic aorta and 
stomach were rapidly removed and placed in a modified Krebs’ solution (composition (mM): 
125 NaCl, 4.6 KCl, 2.5 CaCl2, 15.4 NaHCO3, 1 Na2HPO4, 0.6 MgSO4, 10 D-glucose).  The 
aorta was freed from surrounding fat and other tissues and cut into 5 mm length rings.  Strips 
of the longitudinal muscle (5 x 20 mm) of the gastric fundus (without mucosa) were prepared 
as described by Baxter et al. (1994).  Both tissues were mounted in conventional organ baths 
bubbled with 95%O2/5%CO2 and maintained at 37ºC.  Isometric recordings were made using 
force transducers connected to Powerlab AD converter (AD Instruments) and recorded using 
Chart for Windows (version 5, AD Instruments). 
 
2.4.1. Vasoconstriction in the rat aorta 
 
Rings of aorta were mounted on two longitudinal hooks, one acting as an anchor in the organ 
bath and the other connected to a force transducer.  The preparations were initially stretched to 
a passive tension of 20 mN and then allowed to equilibrate for 30 minutes.  Subsequently, a 
reference contraction was produced by adding 60 mM KCl for 5 minutes before several washes 
and a further 30 minute equilibration period.  Antagonists were added at the beginning of this 
equilibration period.  Subsequently, cumulative additions of 5-APB were added to the bath in 
half-log increments.  Experiments were performed using pairs of rings from the same animal, 
with one ring acting as a control.  
 
2.4.2. Muscle contractions/relaxations in the rat fundus 
 
Strips of gastric fundus were connected to an anchor in the organ bath and the transducer using 
5-0 surgical silk.  The experimental protocol for these experiments was identical to that above 
for rat aorta, except that the reference contraction was elicited by 100 µM methacholine. 
 
2.5. Statistical Analysis 
 
Autoradiography data on [
125
I]RTI-121 and  [
3
H]ketanserin radioligand binding were analyzed 
using a 2-way ANOVA with Tukey’s post-hoc tests. Voltammetric data were analyzed using 
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1-way ANOVA (SigmaStat) with Tukey’s post-hoc tests. 
 
Cumulative concentration-effect data from aorta and fundus were fitted to sigmoid curves 
using Graphpad Prism to determine pEC50 values for agonists.  All other statistical tests were 
also performed using Graphpad Prism.  The effects of the 5-HT2A and 5-HT2B antagonists, 
respectively, were compared with controls by comparing the maximal responses, as pEC50 
values could not be estimated reliably in antagonist-treated preparations.  Comparisons were 
made using unpaired t-tests (with Welch’s correction for unequal standard deviations, as 
appropriate). 
 
Data are presented as mean ± standard error of mean (SEM), with significance set at p < 0.05. 
 
3. Results 
 
3.1. Autoradiography 
 
3.1.1. Competition between 5-APB and [
125
I]RTI121 at the dopamine transporter. 
 
The displacement of [
125
I]RTI121 by 5-APB was examined in both caudate and accumbens and 
Figure 1A shows autoradiograms of relevant brain sections labeled with this radioligand. There 
was a marked concentration-dependent effect of 5-APB on the intensity of iodine-125 signal in 
brain tissue, indicating competition between 5-APB and [
125
I]RTI121. Two-way ANOVA 
revealed no significant effect of brain area (p > 0.05), but there was a significant effect of 5-
APB concentration in both caudate (F = 22.557; p < 0.001) and accumbens (F = 31.709; p < 
0.001) but no brain area X concentration interaction (P > 0.05). Tukey’s test showed that both 
10 and 30 µM 5-APB caused significantly greater displacement of [
125
I]RTI-121 than any 
other concentrations while 3 µM 5-APB caused a significant displacement of [
125
I]RTI-121 
versus controls where no 5-APB was present (Total binding; Fig 1C).  
 
3.1.2. Competition between 5-APB and [
3
H]ketanserin at the 5-HT2A receptor. 
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The displacement of [
3
H]ketanserin by 5-APB was examined in both accumbens and prefrontal 
cortex (PFC). Figure 1B shows representative autoradiograms of brain sections labeled with 
[
3
H]ketanserin – there was an observable reduction in the tritium signal in the cortical and 
accumbens areas, which was dependent on the concentration of 5-APB. This was consistent 
with the competition between 5-APB and the radioligand. Two-way ANOVA revealed no 
significant effect of brain area (p > 0.05), but there was a significant effect of 5-APB 
concentration in both PFC (F = 24.441; p < 0.001) and accumbens (F = 28.121; p < 0.001), but 
no brain area X concentration interaction (P > 0.05). Tukey’s test showed that both 10 µM and 
30 µM 5-APB caused significantly greater displacement of [
3
H]ketanserin than any other 
concentrations while 3 µM 5-APB caused a significant displacement of [
3
H]ketanserin versus 
controls with no 5-APB (Total binding; Fig 1D).  
 
3.2. Dopamine efflux in accumbens brain slices 
 
5-APB has a chemical structure quite similar to 5-HT, therefore, we first tested whether 5-APB 
itself was electroactive, as if it was then it could interfere with our voltammetric dopamine 
measurements. Figures 2c and 2g show that 5-APB was not electroactive; there were no 
oxidation and reduction peaks associated with 5-APB, at least up to 10 µM. 
 
On electrical stimulation (10 pulses at 20 Hz) the mean peak dopamine levels was 218 ± 19 
nM with a reuptake time-constant of 1.25 ± 0.17 s. One-way ANOVA revealed that 5-APB 
showed a concentration dependent increase in evoked dopamine (Figure 3; F = 10.78, p < 
0.001), as determined by the AUC after electrical stimulation. Tukey’s test showed that 10 µM 
5-APB had a greater effect than all other concentrations (p < 0.01). On 2 out of 3 occasions 10 
µM 5-APB caused a small increase (mean = 428 nM) in basal (non-stimulated) levels of 
dopamine (Figures 2b and 2f).  
 
3.3. Effect of 5-APB in the periphery 
 
3.3.1. Vasoconstriction at rat aorta 
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5-APB produced erratic contractile responses with maxima ranging from 7-127% (n=5) of the 
KCl reference contraction, making an analysis of the effect of the 5-HT2A antagonist ketanserin 
(0.1 µM) difficult, although the drug clearly blocked responses in all preparations (not shown).  
The addition of nifedipine to block voltage-gated calcium channels rendered responses to 5-
APB much more consistent between tissues, albeit at the compromise of a loss of amplitude.  
Under these conditions, 5-APB had a pEC50 of 5.11 ± 0.08, with a mean response amplitude of 
15.7 ± 1.4% (n=4); responses were abolished in preparations treated with ketanserin (0.1 µM; 
figure 4A).  Under the same conditions, 5-HT produced responses with pEC50 of 5.38 ± 0.09 
and a maximum of 158.5 ± 9.3% which were also abolished by ketanserin (0.1 µM; not 
shown). 
 
3.3.2. Contractions in rat fundus 
 
5-HT (pEC50 7.643 ± 0.19; n=5), MDMA (pEC50 6.833 ± 0.17; n=6) and 5-APB (pEC50 7.35 ± 
0.34) all caused contractions of rat gastric fundus preparations (figure 4B).  We examined 
MDMA as an internal control, as it is known to act on 5-HT2B receptors.  In comparison to 5-
HT, 5-APB and MDMA appeared to be partial agonists as the maximal responses to these 
drugs were lower than 5-HT itself.  The concentration-effect curves for all three agonists were 
significantly right-shifted by the 5-HT2B antagonist RS 127445 (1 µM; Bonhaus et al., 1999); 
the results for 5-APB are shown in figure 4C. 
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4. Discussion. 
 
We have shown that 5-APB binds to the dopamine transporter, blocks reuptake of dopamine 
and, at high concentrations, causes an increase in basal dopamine. This increase in basal 
dopamine is probably through reverse transport where amphetamine-like compounds can 
displace dopamine from synaptic vesicles (Sulzer et al., 2005). We have also shown that 5-
APB binds to the 5-HT2A receptor in prefrontal cortex and nucleus accumbens and in rat 
vascular studies we have shown that 5-APB is an agonist at both the 5-HT2A and 5-HT2B 
receptors. The present findings suggest potential addictive, hallucinogenic and vasoconstrictive 
properties of 5-APB, which should be of concern to policy makers. Only one previous study 
has examined the pharmacology of 5-APB (Iversen et al., 2013). In radioligand binding studies 
of 49 human molecular targets, Iversen et al., (2013) found 5-APB to have high affinity (pKi > 
6) only at the 5-HT2B (pKi = 7.85), 5-HT2C (pKi = 6.28), α2B (pKi = 6.16), α2C (pKi =6.31), 
DAT (pKi =7.07) and SERT (pKi =6.26). In addition, functional studies in HEK-T cells 
expressing the human 5-HT2B receptor showed that 5-APB had a pEC50 of 7.82 at the 5-HT2B 
site. 
 
Our autoradiographic results suggest that 5-APB competes with [
125
I]RTI-121 at the dopamine 
transporter in a concentration-dependent manner. There is also a concentration-dependent 
competition between 5-APB and [
3
H]ketanserin at 5-HT2A receptors, the site of action of 
hallucinogens (Nichols, 2004; Egan et al., 1998; Passie et al., 2008). To our knowledge, this is 
the first demonstration of 5-APB binding to the dopamine transporter and 5-HT2A receptor in 
rat brain tissue. The present DAT effect is consistent with the recent findings by Iversen et al. 
(2013) derived from in vitro studies on cell lines 
 
The voltammetry studies suggest that 5-APB is not electroactive and does not affect electrode 
sensitivity (Davidson et al., 2000). These functional neurochemistry studies show 5-APB to be 
a modest stimulant with a profile more like amphetamine than cocaine. The effect of 5-APB on 
the AUC of electrically evoked accumbens dopamine is not quite as great as that of stimulants 
such as cocaine, which increase the AUC by 3- and 6-fold at 1 and 10 µM respectively in the 
accumbens core (Yorgason et al., 2011). In the accumbens shell, we saw only a significant 
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increase at 10 µM (5-fold versus baseline) and although 1 µM 5-APB nearly doubled the AUC, 
this was not statistically significant. On the other hand, 5-APB was able to increase basal 
levels of dopamine (Figures 2b and 2f), an effect most often associated with amphetamine-like 
compounds and usually attributed to reverse transport (Sulzer et al., 2005). Typically it is 
found that stimulants have a greater effect on dopamine efflux in the accumbens shell versus 
the core (Pontieri et al., 1996), thus our results are relatively modest. Taken together, the 
increased AUC of electrically evoked dopamine and the increase in basal dopamine, we 
suggest that 5-APB is a modest amphetamine-like stimulant. Although not tested in the present 
study, amphetamine-like drugs have been shown to cause hyperthermia (Levi et al., 2012) and 
neurotoxicity (Davidson et al., 2001). Hyperthermic effects of 5-APB/benzofury have been 
reported by Emergency departments (ACMD report) and by online user groups (Drugs Forum 
website). 
 
While effects on brain transporters and receptors are critical to the rewarding and addictive 
properties of drugs of abuse, it is the effects found in the periphery that are more likely to 
contribute directly to drug-related deaths. Abused drugs, such as the psychostimulants cocaine 
and the amphetamines, are clearly associated with increased risks of cardiovascular 
complications such as myocardial infarction and stroke due to their effects on sympathetic 
neurotransmitter uptake and release (Petitti et al., 1998).  The drugs which are potentially the 
most dangerous are likely to be those that cause a fast and large increase in accumbens 
dopamine levels, carrying higher risks of addiction (Fowler et al., 2001), combined with 
peripheral cardiovascular effects which are likely to be toxic after chronic use (Dawson and 
Moffatt, 2012). 
 
Activation of the 5-HT system throughout the body has vasopressor effects and 5-HT receptors 
have been considered as potential targets for novel hypertensive drugs. Indeed, the 5-HT2A 
receptor antagonist which we have used in this study, ketanserin, was a potent antihypertensive 
drug, but was withdrawn due to associations with torsade de pointes (Nagatomo et al., 2004). 
The hallucinogen LSD appears to act as a partial agonist of both 5-HT2A and 5-HT1A receptors 
(Halberstadt and Geyer, 2011; Passie et al., 2008), with effects via 5-HT2A receptors 
predominating. The two main receptors expressed by vascular smooth muscle are 5-HT2A and 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 14 
5-HT1B (Kaumann and Levy, 2006) and their expression varies between vascular beds. For 
example, 5-HT1B receptors predominate in cerebral arteries while in most other arteries 5-HT2A 
receptors are most highly expressed. The displacement of ketanserin in our ligand binding 
studies would suggest that 5-APB might be vasoactive. We thus examined the effects of 5-
APB in the rat aorta and found it to cause vasoconstriction, an effect completely inhibited by 
ketanserin.   
 
In our initial experiments 5-APB produced contractions of rat aorta that differed markedly in 
efficacy from preparation to preparation, a phenomenon not observed in the case of 5-HT 
itself.   We found that after blockade of voltage-gated calcium channels with nifedipine, the 
erratic behaviour of the preparations was reduced and more consistent results were obtained.  
Interestingly, nifedipine had much less of an effect on the more reproducible responses to 5-
HT (not shown) than it did on those in response to 5-APB, an observation we have made 
previously with hallucinogenic 5-HT2A agonists in this assay (Dawson & Moffatt, 2012, which 
may relate to agonist-dependent signalling or functional selectivity (Abbas & Roth, 2008).  
Although the erratic responses to 5-APB in the absence of nifedipine make it difficult to 
comment on the efficacy of this drug, we note that the largest response produced (127%) is 
still less than the mean maximum for 5-HT (158%), suggesting that this compound is a partial 
agonist of 5-HT2A receptors, in common with most hallucinogenic 5-HT2A agonists (Glennon, 
1990). It is uncertain if the extreme variability in vascular responsiveness to 5-APB that we 
have shown here and found with other hallucinogenic 5-HT2A agonists (manuscript in 
preparation) has any significance in man, but may relate to individual adverse effects of the 
drug. 
 
The development of heart valve fibrosis is thought to be mediated via activation of 5-HT2B 
receptors.  Drugs such as the anorexic fenfluramine and the anti-Parkinson drug pergolide, 
which both activate the 5-HT2B receptor, have been withdrawn because of their implication in 
valvulopathy after long-term use (Bhattacharyya et al., 2009; Hutcheson et al., 2011; Rothman 
and Baumann, 2002; Rothman et al., 2000). The chronic use of legal highs with similar action 
at 5-HT2B receptors may produce a similar toxic effect. Ecstasy (MDMA) is an abused drug 
with such a risk profile (Setola et al., 2003). Indeed, MDMA directly induces heart valve 
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fibroblast proliferation in vitro via 5-HT2B receptors (Setola et al., 2003). Valvulopathies are 
found in regular MDMA users, many of whom take MDMA only on weekends but over a 
period of several months or years (Bhattacharyya et al., 2009). A simple and sensitive in vitro 
assay for acute effects at the 5-HT2B receptor is the rat gastric fundus contraction assay, first 
described by (Sir) John Vane. Here we found 5-APB to cause contraction of the rat fundus, an 
effect antagonised by the specific 5-HT2B receptor antagonist RS127445 (Bonhaus et al., 
1999). We also found 5-HT and MDMA to cause contraction of the fundus, with 5-APB 
having a greater efficacy than MDMA, a drug already linked to valvulopathies (Bhattacharyya 
et al., 2009). As in the 5-HT2A assay (above), 5-APB appeared to be a partial agonist at the 5-
HT2B receptor, as is the case for MDMA (present study; Setola et al., 2003) and – even more 
so – the MDMA metabolite 3,4-methylenedioxyamphetamine (MDA; Setola et al., 2003). The 
submicromolar potency of 5-APB at 5-HT2B receptors is of some concern.  Indeed, of all the 
assays examined in this study 5-APB had the greatest potency in this system. Activation of 5-
HT2B receptors is inevitable if users imbibe enough 5-APB to interfere with monoamine 
reuptake and release – the principle effect sought by users. 
 
There are a number of limitations to this study that should be considered. First the work was all 
done in adolescent male rats and extrapolation of these results to other age groups or females 
should be done with caution. Second, we only examined acute effects of 5-APB and these were 
examined in vitro. It would be of interest to examine the long-term effects of 5-APB on 
behaviour and the neuro- and cardiovascular systems. In particular, to determine if this drugs is 
addictive, and also to test its proposed cardiotoxicity and possibly, given its amphetamine-like 
profile, whether it causes hyperthermia and  even neurotoxicity. 
 
In conclusion, we have shown that 5-APB is a stimulant with multiple effects on the 
dopaminergic system.  This drug also has affinity for 5-HT2A and 5-HT2B receptors, which 
have the potential for cardiovascular harm, including valvulopathy. This combination of 
addiction potential and cardiovascular toxicity almost certainly represents a public health 
problem. 
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Figure 1. Binding of 5-APB at the dopamine transporter and 5-HT2A receptor sites. A: 
Representative computer-enhanced images of brain slices incubated with the selective 
dopamine transporter ligand [
125
I]RTI121 and exposed to increasing concentrations of 5-APB. 
Note the 5-APB concentration-dependent reduction in the radioligand signal intensity in the 
caudate and accumbens. B: Representative computer-enhanced images of brain slices 
incubated with the 5-HT2A receptor ligand [
3
H]ketanserin and exposed to increasing 
concentrations of 5-APB. Note the 5-APB concentration-dependent reduction in the 
radioligand signal intensity in the prefrontal cortex. C: Pooled data from 6 rats showing the 
concentration response curves for displacement of [
125
I]RTI121 by 5-APB in both the caudate 
(CPu ●) and accumbens (NAc ○), IC50s are 4.1 and 2.2 x 10
-5
M respectively. D: Pooled data 
from 5 rats showing the concentration response curves for displacement of [
3
H]ketanserin by 
5-APB in both the NAc (○) and prefrontal cortex (PFC ●), IC50s are 3.9 and 6.5 x 10
-6
M 
respectively. Values and means ± SEM, n = 5/6. 
 
Figure 2. Left panel: Raw data after application of 5-APB to the accumbens slice and 
calibrations. (a) typical calibration in 5 µM dopamine (DA). (b) typical experiment where 
dopamine is electrically evoked every 5 min (upward arrows), after 3 baseline stimulations 5-
APB is added to the superfusate, within 10 min there is an increase in basal (non-stimulated) 
dopamine levels. (c) calibration of carbon electrode with 10 µM 5-APB. It can be seen that 5-
APB does not affect our signal, thus the increase in the signal seen in (b *) can be attributed to 
dopamine. Right panel: 5-APB increases basal levels of dopamine in the accumbens. (d) 
the input voltage applied to the carbon electrode which goes from 0 to -1, up to +1.4, back to -
1 and finally back to 0 V at 480V/s. The whole voltage scan takes 20 ms. (e) shows the 
oxidation and reduction peaks at the carbon electrode after applying 5 µM dopamine, data is 
from the calibration shown in Fig 2a and taken at the time denoted by *. (f) oxidation (at +0.6 
V) and reduction (at -0.2 V) peaks from dopamine release in the accumbens, after application 
of 10 µM 5-APB, as shown in Fig 2b and taken at the time denoted by * i.e. at the peak effect. 
Note that the oxidation peak is at the same place for both exogenous (a) and endogenous (b) 
dopamine. (g) the lack of effect of 5-APB, when applied to the electrode (from 2c*), in the 
absence of neural tissue. These data show that the peak seen in (b) is from release of dopamine 
and not oxidation of 5-APB, and that 5-APB does not affect electrode sensitivity. 
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Figure 3. Effect of 5-APB on electrically evoked dopamine in the accumbens shell. Left 
panel shows representative raw data of electrically evoked dopamine efflux in the accumbens 
shell before application of 5-APB (control) and after 60 min of 5-APB at 0.1, 1 or 10 µM. The 
peak dopamine level evoked, on each of the control stimulation, is about 300 nM dopamine 
and 20 s of data is shown for each efflux event. Electrical stimulations are given at the upward 
arrow. Right panel shows the concentration dependent increase in dopamine efflux (AUC) 
after application of 5-APB. Values are means ± SEM, n = 3-6. *P < 0.05 versus all other 
groups. 
 
Fig 4. Effect of 5-APB on 5-HT2 receptors in rat aorta and fundus. A. 5-APB caused 
contraction of rat aorta, an effect completely blocked by the 5-HT2A receptor antagonist 
ketanserin (0.1 µM). B. 5-HT, 5-APB and MDMA all caused contraction of rat fundus in a 
concentration dependent manner with the order of potency being 5-HT > 5-APB > MDMA. C. 
The effect of 5-APB in the rat fundus was attenuated by the 5-HT2B receptor antagonist  
RS127445 (1 µM). Values are means ± SEM, n = 4-6. 
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Highlights 
 
 5-APB (Benzofury) has been associated with 10 recent drug-related deaths in the UK 
  
 5-APB displaces radioligands at the dopamine transporter and 5-HT2A receptor 
 
 Voltammetric assessment of 5-APB on accumbens dopamine suggests amphetamine-
like effects 
 
 5-APB contractions of rat aortic preparations suggest potential hypertensive effects 
 
 5-APB contractions of rat fundus predict potential valvulopathies. 
